Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485960 | 0.86 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL610128 | 0.84 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL16824590 | 0.84 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL16824591 | 0.84 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL31048410 | 0.78 | ATM (0.42) | HSD17B10SMN1; SMN2ATMNR1H2NR1H3 | |
| SCHEMBL1631708 | 0.77 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL73359 | 0.77 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL73360 | 0.77 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL31048380 | 0.75 | ATM (0.41) | HSD17B10SMN1; SMN2ATMNR1H2NR1H3 | |
| SCHEMBL18027 | 0.75 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2LMNANR1H2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361743-B2 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | PFIZER INC (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1814893-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060148722-A1 | Novel lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-07-06 | — | — | US | disclosed |
| WO-2006055070-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148722-A1 | Novel lincomycin derivatives possessing antibacterial activity | LCLAT1, LAS1L, NRDC | HSD17B10 1397/4885SMN1; SMN2 4232/4885NPC1 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.